Literature DB >> 21540470

The secrets of a successful clinical trial: compliance, compliance, and compliance.

Pál Czobor1, Phil Skolnick.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21540470      PMCID： PMC3109858          DOI： 10.1124/mi.11.2.8

Source DB:  PubMed          Journal:  Mol Interv        ISSN： 1534-0384


× No keyword cloud information.
  13 in total

Review 1.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

Review 2.  Triple reuptake inhibitors ("broad spectrum" antidepressants).

Authors:  Phil Skolnick; Anthony S Basile
Journal:  CNS Neurol Disord Drug Targets       Date:  2007-04       Impact factor: 4.388

3.  What role does measuring medication compliance play in evaluating the efficacy of naltrexone?

Authors:  Alicia M Baros; Patricia K Latham; Darlene H Moak; Konstantin Voronin; Raymond F Anton
Journal:  Alcohol Clin Exp Res       Date:  2007-04       Impact factor: 3.455

4.  A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain.

Authors:  M Roland; R Morris
Journal:  Spine (Phila Pa 1976)       Date:  1983-03       Impact factor: 3.468

5.  Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor.

Authors:  Phil Skolnick; Piotr Popik; Aaron Janowsky; Bernard Beer; Arnold S Lippa
Journal:  Eur J Pharmacol       Date:  2003-02-14       Impact factor: 4.432

Review 6.  Lost in translation: neuropsychiatric drug development.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Sci Transl Med       Date:  2010-12-08       Impact factor: 17.956

7.  Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain.

Authors:  Anthony S Basile; Aaron Janowsky; Krystyna Golembiowska; Magdalena Kowalska; Eyal Tam; Morris Benveniste; Piotr Popik; Agnieszka Nikiforuk; Martyna Krawczyk; Gabriel Nowak; Philip A Krieter; Arnold S Lippa; Phil Skolnick; Elena Koustova
Journal:  J Pharmacol Exp Ther       Date:  2007-02-26       Impact factor: 4.030

8.  Pharmacokinetics, disposition, and metabolism of bicifadine in humans.

Authors:  Philip A Krieter; Mark Gohdes; Timothy J Musick; Frederick P Duncanson; William E Bridson
Journal:  Drug Metab Dispos       Date:  2007-11-08       Impact factor: 3.922

9.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

Authors:  F Xavier Pi-Sunyer; Louis J Aronne; Hassan M Heshmati; Jeanne Devin; Julio Rosenstock
Journal:  JAMA       Date:  2006-02-15       Impact factor: 56.272

10.  The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity.

Authors:  Joseph P Tizzano; D Sloan Stribling; Diego Perez-Tilve; Alison Strack; Andrea Frassetto; Richard Z Chen; Tung M Fong; Lauren Shearman; Philip A Krieter; Matthias H Tschöp; Phil Skolnick; Anthony S Basile
Journal:  J Pharmacol Exp Ther       Date:  2007-12-18       Impact factor: 4.030
View more
  26 in total

Review 1.  Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Authors:  Horrick Sharma; Soumava Santra; Aloke Dutta
Journal:  Future Med Chem       Date:  2015-11-30       Impact factor: 3.808

2.  Electrochemical Aptamer-Based Sensors for Improved Therapeutic Drug Monitoring and High-Precision, Feedback-Controlled Drug Delivery.

Authors:  Philippe Dauphin-Ducharme; Kyungae Yang; Netzahualcóyotl Arroyo-Currás; Kyle L Ploense; Yameng Zhang; Julian Gerson; Martin Kurnik; Tod E Kippin; Milan N Stojanovic; Kevin W Plaxco
Journal:  ACS Sens       Date:  2019-10-15       Impact factor: 7.711

Review 3.  From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders.

Authors:  Jane B Acri; Alan J Cross; Phil Skolnick
Journal:  Psychopharmacology (Berl)       Date:  2016-12-20       Impact factor: 4.530

4.  Subtherapeutic Acetazolamide Doses as a Noninvasive Method for Assessing Medication Adherence.

Authors:  Aidan J Hampson; Jennifer R Schroeder; Kayla N Ellefsen; Luba Yammine; David H Epstein; Kenzie L Preston; Marilyn A Huestis; Christopher D Verrico
Journal:  Clin Pharmacol Ther       Date:  2020-07-11       Impact factor: 6.875

5.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

Review 6.  How the EMERGE guideline on medication adherence can improve the quality of clinical trials.

Authors:  Lina Eliasson; Sarah Clifford; Amy Mulick; Christina Jackson; Bernard Vrijens
Journal:  Br J Clin Pharmacol       Date:  2020-02-28       Impact factor: 4.335

7.  Tobacco Industry Research on Nicotine Replacement Therapy: "If Anyone Is Going to Take Away Our Business It Should Be Us".

Authors:  Dorie Apollonio; Stanton A Glantz
Journal:  Am J Public Health       Date:  2017-08-17       Impact factor: 9.308

Review 8.  Design and conduct of confirmatory chronic pain clinical trials.

Authors:  Nathaniel Katz
Journal:  Pain Rep       Date:  2020-12-18

9.  A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials.

Authors:  Aidan J Hampson; Shanna Babalonis; Michelle R Lofwall; Paul A Nuzzo; Phillip Krieter; Sharon L Walsh
Journal:  J Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.153

10.  The relationship between maternal self-efficacy, compliance and outcome in a trial of vitamin D supplementation in pregnancy.

Authors:  M Barker; S D'Angelo; G Ntani; W Lawrence; J Baird; M Jarman; C Vogel; H Inskip; C Cooper; N C Harvey
Journal:  Osteoporos Int       Date:  2016-08-22       Impact factor: 4.507
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.